Literature DB >> 15948034

St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

Zeping Hu1, Xiaoxia Yang, Paul Chi-Liu Ho, Eli Chan, Sui Yung Chan, Congjian Xu, Xiaotian Li, Yi-Zhun Zhu, Wei Duan, Xiao Chen, Min Huang, Hongyuan Yang, Shufeng Zhou.   

Abstract

CPT-11 is a DNA topoisomerase I inhibitor for the therapy of colorectal cancer, whereas St. John's Wort (Hypericum perforatum, SJW) is a widely used herbal anti-depressant. This study aimed to investigate the effects of co-administered SJW on the toxicities and pharmacokinetics of CPT-11 and the underlying mechanisms. The body weight loss, gastrointestinal and hematological toxicities induced by CPT-11, and the pharmacokinetic parameters of CPT-11 were evaluated in rats pretreated with SJW or vehicle. Rats treated with CPT-11 alone experienced rapid decrease in body weight, whereas co-administration of SJW with CPT-11 resulted in lesser body weight loss. The gastrointestinal and hematological toxicities following CPT-11 injection were both alleviated in the presence of SJW. The rat pharmacokinetics of both CPT-11 and its metabolite SN-38 were significantly altered in presence of SJW. In conclusion, co-administered SJW significantly ameliorated the toxicities induced by CPT-11. The protective effect of SJW may be partially due to pharmacokinetic interaction between CPT-11 and SJW.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948034     DOI: 10.1007/s11095-005-4585-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  98 in total

Review 1.  St John's wort: Prozac from the plant kingdom.

Authors:  G Di Carlo; F Borrelli; E Ernst; A A Izzo
Journal:  Trends Pharmacol Sci       Date:  2001-06       Impact factor: 14.819

Review 2.  Evolving role of oral chemotherapy for the treatment of patients with neoplasms.

Authors:  F A Greco
Journal:  Oncology (Williston Park)       Date:  1998-03       Impact factor: 2.990

3.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

Authors:  Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Dorothee Semiond; Maja J A deJonge; Ferry A L M Eskens; Judith ter Steeg; Johan Selleslach; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; A T van Oosterom
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

Review 5.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Authors:  R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

Review 6.  Gastrointestinal toxicity or irinotecan.

Authors:  J R Hecht
Journal:  Oncology (Williston Park)       Date:  1998-08       Impact factor: 2.990

7.  Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.

Authors:  E Gupta; A R Safa; X Wang; M J Ratain
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

Review 8.  Pharmacokinetic interactions of drugs with St John's wort.

Authors:  Shufeng Zhou; Eli Chan; Shen-Quan Pan; Min Huang; Edmund J D Lee
Journal:  J Psychopharmacol       Date:  2004-06       Impact factor: 4.153

9.  Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.

Authors:  L P Rivory; M C Haaz; P Canal; F Lokiec; J P Armand; J Robert
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

10.  Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.

Authors:  Akinobu Kurita; Shoichi Kado; Norimasa Kaneda; Masaharu Onoue; Shusuke Hashimoto; Teruo Yokokura
Journal:  Cancer Chemother Pharmacol       Date:  2003-08-06       Impact factor: 3.333

View more
  8 in total

1.  Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation.

Authors:  Qiaoshi Lian; Jun Xu; Shanshan Yan; Min Huang; Honghua Ding; Xiaoyu Sun; Aiwei Bi; Jian Ding; Bing Sun; Meiyu Geng
Journal:  Cell Res       Date:  2017-04-14       Impact factor: 25.617

Review 2.  Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.

Authors:  Sridhar Mani; Mohammed Ghalib; Imran Chaudhary; Sanjay Goel
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

3.  How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints?

Authors:  J Hübner; K Münstedt; R Mücke; O Micke
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-10       Impact factor: 2.915

Review 4.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

Review 5.  Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.

Authors:  Arunima Biswas; Sridhar Mani; Matthew R Redinbo; Matthew D Krasowski; Hao Li; Sean Ekins
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

6.  The effect of St John's wort on the pharmacokinetics of docetaxel.

Authors:  Andrew K L Goey; Irma Meijerman; Hilde Rosing; Serena Marchetti; Marja Mergui-Roelvink; Marianne Keessen; Jacobus A Burgers; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 5.577

7.  Use of Complementary and Alternative Medicine in Children with Cancer: A Study at a Swiss University Hospital.

Authors:  Tatjana Magi; Claudia E Kuehni; Loredana Torchetti; Laura Wengenroth; Sonja Lüer; Martin Frei-Erb
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

Review 8.  Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.

Authors:  Xiu-Lai Zhang; Meng Chen; Ling-Ling Zhu; Quan Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-11       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.